Jack Henry & Associates (JKHY) has been heavily featured in the recent press. The company has seen both upgrades and downgrades from analysts.
Wolfe Research and
Raymond James have upgraded JKHY, raising the stock rating to 'Strong-Buy' and 'Outperform'. This has been based on the company's
strong financial performance and the recent share price strength. Furthermore, despite some declines recently, the company has seen substantial gains in its share price. JKHY has also been bolstering its
local commitment by strengthening ties with various banks and financial institutions, such as SanCap and Mercantile Bank. It has been praised for its reliable compounding, solid outlook and focus on innovation and growth. JKHY also posted better-then-expected sales in Q3 and its Q1 earnings and revenues exceeded estimates. The company's fiscal 2025 results and dividends, the launch of 'MyFinancialHealth' on its digital platform and the acquisition of fintech firm provide further positive news. However, some feel the shares aren't as cheap as they would like them to be.
UBS maintains a 'Neutral' rating but has raised the price target to $195.
Henry Jack Associates JKHY News Analytics from Thu, 08 May 2025 07:00:00 GMT to Sat, 10 Jan 2026 15:52:05 GMT -
Rating 8
- Innovation 7
- Rumor 6
